RZLV Borrow Costs Triple as Shorts Build Into Earnings

The Street view on Rezolve AI is hard to pin down cleanly. No analyst data was available for this note, so the fundamental picture has to be read through the valuation and factor lens. The numbers are not encouraging on quality: EV/EBITDA of roughly -169 reflects a company that is not yet profitable, and the 30-day move in that multiple has gone further negative, not less so. ORTEX factor scores rank the stock in the 2nd percentile on short score and the 1st percentile on availability — both extremes — while the sector composite sits at the 50th percentile. That combination points to a company the market has not abandoned on fundamentals alone, but one where the technical pressure from the short side is severe. The Growth pillar, at 91.2 in recent ORTEX scoring, remains the bull case: the AI commerce and monetisation narrative is intact. The bear case is execution — negative return on assets, an f-score of 3, and integration risk from an active M&A posture.

Insider activity offers a small counterweight. CEO and founder Daniel Wagner bought just over 800,000 shares at $4.00 in early April, spending roughly $3.25 million in two transactions. A director added another ~96,000 shares at $2.78 in mid-May. Net insider buying over the past 90 days is approximately 908,000 shares worth $3.5 million. The purchases were made above the current price of $2.33, meaning Wagner is sitting on a mark-to-market loss of roughly 40%. That cuts both ways: it can be read as conviction from the inside, or as a signal that management's sense of value has not yet been validated by the tape. The stock is down 18% over the past week and down about 3% over the past month — the week's move is notably sharp.

Peer context reinforces that RZLV is not falling in isolation. ARQQ dropped 23% on the week, SOUN fell 20%, and HOLO shed 17% — the entire small-cap AI cohort is under pressure. RZLV's 18% weekly decline is broadly in line with the peer group, suggesting the immediate move is more sector than stock-specific. That peer weakness also matters for the short thesis: when correlated names are selling off simultaneously, forced covering or fresh shorting tends to concentrate in the names where borrow is available — and at 5% availability, RZLV has very little cushion left.

With earnings scheduled for June 26, the next two weeks will test whether the current borrow squeeze holds or the stock move forces a resolution — specifically, whether any further price decline prompts covering that relieves availability pressure, or whether the short build continues into the print.